Abstract
Background Systemic treatment with tyrosine-kinase inhibitors (TKI) is the standard of care for advanced non-small cell lung cancer (NSCLC) patients who harbor EGFR mutations. Over 90% of patients have two most frequent mutations: deletion of exon 19 and exon 21 L858R substitution. In such patients, first line treatment with TKI is strongly recommended and produces a high response rate. It is less clear how patients harboring other, rare mutations will response to TKI, and experiences are still sparse. We analyzed the response to gefitinib, applied in first line treatment for advanced Serbian lung adenocarcinoma patients, in the last three years.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
